The objectives of this study are: 1) To measure the association between in utero exposure to prescription opioids during early pregnancy and primary neurulation defects. 2) To evaluate whether the risk of primary neurulation defects (i.e., craniorachischisis, anencephalus, and myelomeningocele) differs among live births exposed compared to live births unexposed to maternal prescription opioids from 18 to 56 days after last menstrual period.
Risk of NTD among Live Births Exposed to Maternal Rx Opioids during Early Pregnancy
Investigator: Li, De-Kun
Funder: U.S. Food and Drug Administration
